Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04499183
Other study ID # NL74418.081.20
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 8, 2020
Est. completion date February 1, 2021

Study information

Verified date October 2020
Source Wageningen University
Contact MARA VAN TRIJP
Phone 0317 484 067
Email mara.vantrijp@wur.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nowadays there is a strong interest in optimising human health through manipulation of non-digestible carbohydrates (NDC). NDC can be used as substrates by gut microbiota, which results in NDC degradation, production of fermentation products, such as short-chain fatty acids (SCFA), and a shift in microbiome composition and activity. It is hypothesized that SCFAs mediate parts of the beneficial effects of NDC. In mice, the influx of SCFA into the host correlated strongly with improvements of markers of the metabolic syndrome, in contrast to the concentrations of SCFA in the proximal colon. Therefore, the influx of short chain fatty acids (SCFA) into the body may be of high importance in improving metabolism. There is a need for more studies in humans to trace the life course of SCFA and their regulatory role in human metabolism. To study this inner world of bacterial products in humans, we will use a nasal-intestine catheter that can be used for delivery of components and sampling chyme in the proximal colon. Before the proposed methodology can be applied in a large intervention study, a small scale feasibility study needs to be performed that addresses colonic placement of the nasal-intestine cathether and colonic sampling of regular and NDC-enriched chyme samples. We will investigate the acute fermentation of fructo- and galacto-oligosaccharides in the proximal colon. Moreover, we will deliver 13C-labelled SCFA via a naso-intestinal catheter to quantify the fluxes of SCFA production, interconversion and uptake by the host. A small-scale, 7-day parallel feasibility trial, N=5 subjects will receive GOS/FOS supplements (mix 1:1 ratio, 15 gram/day), and N=5 other subjects will receive placebo supplements (isocaloric maltodextrin, 12 gram/day). At the last day of the supplementation period, the catheter will be placed, and afterwards participants stay maximum 5 hours in the hospital, to ensure progression of the nose-intestine catheter. After an overnight fast, subjects will visit the hospital again for measurements. Subjects will consume a NDC bolus (200 mL tap water, 5 gram fructo-oligosaccharides, 5 gram galacto-oligosaccharides, non-absorbable marker (PEG-4000). Afterwards, they are not allowed to eat for 6.5 hours. Isotopically 13C-labelled SCFAs will be delivered in the proximal colon. Blood and colonic luminal samples, breath samples, faeces and urine will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date February 1, 2021
Est. primary completion date February 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 60 Years
Eligibility Inclusion criteria: - Males - Age 18-60yrs - BMI between 18.5 and 30 kg/m2 - Regular bowel movement (defaecation on average once a day) - Signed informed consent Exclusion criteria: - Having a history of medical or surgical events that, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results of the study (e.g. diabetes, cardiovascular disease, gastrointestinal disease, renal failure, cancer, infectious disease, nose/throat). - Having a history of surgical events of the gastro-intestinal tract (e.g. bariatric surgery/gastric bypass surgery) - Presence of swallowing disorder - Use of any prescribed or non-prescribed medication (other than paracetamol) including antacids, analgesics, and herbal remedies during the three (3) weeks prior to study start. - Being lactose intolerant - Follows a vegan diet - Use of antibiotics within 3 months of starting the study or planned during the study - Use of pro- or prebiotics (e.g. galacto-oligosaccharides, fructo-oligosaccharides) - Constipation/infrequent bowel movement (less than 3 times defaecation per week) - Abuse of drugs/alcohol (alcohol: >4 consumptions/day or >21 consumptions/week) - Smoker - Having diarrhoea within 1 month prior to the study start - Personnel of Wageningen University, Division of Human Nutrition, their partner and their first and second degree relatives - Participation in another biomedical study or other research from the Division of Human Nutrition - Not willing to be exposed to fluoroscopy - Having a hemoglobin of <8.5 mmol/L - Having blood vessels that are too difficult for inserting a cannula - Not having a general practitioner

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
fructo- and galacto-oligosaccharides
15 gram/day fructo- and galacto-oligosaccharides

Locations

Country Name City State
Netherlands Wageningen University and Research Wageningen

Sponsors (1)

Lead Sponsor Collaborator
Wageningen University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Concentrations of non-digestible markers TiO2 and PEG-4000 inside the intestine Between 0 and 400 minutes
Primary Concentrations of carbohydrates mono-, di-, tri-, oligo- and polysaccharides in the intestinal lumen Between 0 and 400 minutes
Primary Relative microbiota composition and metabolites Microbiota and metabolites inside the intestine Between 0 and 400 minutes
Primary Concentrations of plasma metabolites organic acids, amino acids, glucose, cholesterol, fatty acids and bile acids in blood Between 0 and 400 minutes
Primary Catheter placement in the colon To show placement of a naso-intestinal catheter in the proximal colon. After 1 week
Primary Volume of colon sample (mL) To check whether enough material for analysis is obtained if the catheter system takes samples in the proximal colon of participants. Between 0 and 400 minutes
Primary Concentrations of SCFAs (13C isotopic) enrichments of SCFAs inside intestinal lumen Between 0 and 400 minutes
Secondary Concentrations of urine metabolites hippurate, di- en tri-methylamine, acetaldehydes, taurine, glycine, glucuronic acid conjugates, and bile acid profiles (conjugates) After 0 and 120 minutes
Secondary Questionnaires about (dis)comfort of study procedures Questions about study procedures After 1 week
Secondary Relative microbiota composition and metabolite concentrations Microbiota and metabolome in faeces After 1 week
See also
  Status Clinical Trial Phase
Completed NCT05726435 - Effects of Soluble Dietary Fiber on Sport Efficiency and Fatigue Delay in Top Basketball Players N/A
Completed NCT05634044 - Validating eNose Measurement of Daily Fiber Intake N/A
Completed NCT03848546 - Stimulating Fiber Intake Via Personalized Dietary Advice N/A
Completed NCT04013607 - Fiber Fermentation Kinetics Inside the Gut, and Utilization of Bacterial Metabolites N/A
Withdrawn NCT04438473 - Pectin Supplemented Enteral Feedings in Critically Ill Patients N/A
Completed NCT04352231 - Luxembourgish Fiber Cohort N/A
Completed NCT03387345 - Barley and Rice Mixture Effects on Blood Glucose N/A
Recruiting NCT04690075 - Effect of Dietary Fiber on Metabolism, Inflammation and Nutritional Status in Patients With Chronic Diseases N/A
Completed NCT03796286 - A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Glucose and Insulin Responses N/A
Recruiting NCT04611217 - Dietary Fiber Effects on the Microbiome and Satiety N/A
Completed NCT01321736 - Gut Health Response to Dietary Fiber N/A